Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study

NCT02860065 is registered in ClinicalTrials.gov with Chase Pharmaceuticals Corporation, an affiliate of Allergan plc as lead sponsor.

NCT NCT02860065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2016
Completion date
June 30, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease